Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer

OncoTargets and Therapy
Shiven B PatelI Garrido-Laguna

Abstract

Targeted therapies against EGFR, vascular endothelial growth factor, and vascular endothelial growth factor receptor have expanded treatment options for patients with metastatic colorectal cancer (mCRC). Unfortunately, biomarkers to identify patients that are most likely to derive benefit from targeted therapies in this disease are still needed. Indeed, only RAS mutations have been identified as predictive of lack of benefit from monoclonal antibodies against EGFR in patients with mCRC. Panitumumab is a fully humanized monoclonal antibody against EGFR. In this study, we review data to support the use of panitumumab in combination with a chemotherapy backbone, in the first line setting in patients with RAS wild-type mCRC. Ongoing efforts are aimed at identifying smaller subsets of patients within the RAS wild-type group that will derive the largest benefit from anti-EGFR therapy. In the meantime, treatment with anti-EGFR therapy should be reserved for patients with RAS wild-type mCRC.

Citations

Jul 12, 2017·Journal of breast cancer·Gábor Rubovszky, Zsolt Horváth
Jan 13, 2018·Apoptosis : an International Journal on Programmed Cell Death·Ali RazaghiSpencer B Gibson

❮ Previous
Next ❯

Methods Mentioned

BETA
transgenic
xenografts
PCR
biopsies
exome sequencing

Software Mentioned

XenoMouse
COSMIC SANGER

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

© 2022 Meta ULC. All rights reserved